Welcome to LookChem.com Sign In|Join Free
  • or
4-Hydroxycyclophosphamide is a phosphorodiamide compound that consists of 2-amino-1,3,2-oxazaphosphinan-4-ol 2-oxide with two 2-chloroethyl groups attached to the exocyclic nitrogen. It is a derivative of cyclophosphamide, a widely used alkylating agent in cancer chemotherapy.

40277-05-2

Post Buying Request

40277-05-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

40277-05-2 Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxycyclophosphamide is used as an intermediate in the synthesis of various anticancer drugs for its alkylating properties. It plays a crucial role in the development of pharmaceuticals that target cancer cells by forming covalent bonds with cellular macromolecules, such as DNA, and disrupting their function.
Used in Anticancer Applications:
4-Hydroxycyclophosphamide is used as an anticancer agent for its ability to cross-link DNA strands, leading to the inhibition of DNA replication and transcription. This action results in the prevention of cancer cell proliferation and the induction of apoptosis, ultimately contributing to the regression of tumor growth.
Used in Drug Delivery Systems:
In the field of drug delivery, 4-hydroxycyclophosphamide is used as a component in the development of targeted drug delivery systems. These systems aim to improve the bioavailability, specificity, and therapeutic efficacy of anticancer drugs by encapsulating 4-hydroxycyclophosphamide within nanoparticles, liposomes, or other carriers. This approach helps to reduce systemic toxicity and side effects associated with traditional chemotherapy.
Used in Research and Development:
4-Hydroxycyclophosphamide is also utilized in research and development for the study of its chemical properties, mechanisms of action, and potential applications in various biological and medical fields. This includes the investigation of its interactions with different cellular targets, the development of novel drug combinations, and the exploration of its potential use in personalized medicine strategies.

Synthesis Reference(s)

Journal of the American Chemical Society, 95, p. 7535, 1973 DOI: 10.1021/ja00803a070

Check Digit Verification of cas no

The CAS Registry Mumber 40277-05-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,2,7 and 7 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 40277-05:
(7*4)+(6*0)+(5*2)+(4*7)+(3*7)+(2*0)+(1*5)=92
92 % 10 = 2
So 40277-05-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H15Cl2N2O3P/c8-2-4-11(5-3-9)15(13)10-7(12)1-6-14-15/h7,12H,1-6H2,(H,10,13)

40277-05-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-hydroxycyclophosphamide

1.2 Other means of identification

Product number -
Other names 4-Hydroxycyclophosphamid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:40277-05-2 SDS

40277-05-2Synthetic route

cyclophosphamide
50-18-0

cyclophosphamide

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

Conditions
ConditionsYield
With dihydrogen peroxide; unspecific peroxygenase of Marasmius rotula In aq. acetate buffer at 25℃; for 1h; Reagent/catalyst; Enzymatic reaction;32%
With dihydrogen peroxide; iron(II) sulfate
Multi-step reaction with 2 steps
1: (i) O3, (ii) H2O2
2: P(OEt)3
View Scheme
4-hydroperoxycyclophosphamide
39800-16-3, 146566-40-7

4-hydroperoxycyclophosphamide

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

Conditions
ConditionsYield
With triethyl phosphite
cyclophosphamide
50-18-0

cyclophosphamide

A

Carboxyphosphamide
22788-18-7

Carboxyphosphamide

B

aldophosphamide
35144-64-0

aldophosphamide

C

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

D

4-ketocyclophosphamide mustard
27046-19-1, 69580-11-6, 69580-12-7

4-ketocyclophosphamide mustard

Conditions
ConditionsYield
pharmacokinetics, metabolism;
4-hydroperoxycyclophosphamide
39800-16-3, 146566-40-7

4-hydroperoxycyclophosphamide

A

aldophosphamide
35144-64-0

aldophosphamide

B

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

Conditions
ConditionsYield
With triphenylphosphine In dichloromethane at 5℃; for 0.166667h; Rate constant;
iminocyclophosphamide
84489-09-8

iminocyclophosphamide

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

Conditions
ConditionsYield
With Tris buffer (1.0 M); dihydrogen peroxide at 30℃; Rate constant;
/PHEBG305--160/

/PHEBG305--160/

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

Conditions
ConditionsYield
With sodium thiosulfate In water
cyclophosphamide
50-18-0

cyclophosphamide

A

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

B

4-peroxycyclophosphamide
51274-71-6, 146566-41-8

4-peroxycyclophosphamide

C

4-ketocyclophosphamide mustard
27046-19-1, 69580-11-6, 69580-12-7

4-ketocyclophosphamide mustard

Conditions
ConditionsYield
With dihydrogen peroxide; iron(II) sulfate In water at 0 - 10℃; Fenton Reaction;
N-hydroxyurea
127-07-1

N-hydroxyurea

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

2-(Bis-(2-chlorethyl)-amino)-r-2-oxo-tetrahydro-2H-1,3,2-oxazaphosphorin-trans-4-yl-oxyharnstoff

2-(Bis-(2-chlorethyl)-amino)-r-2-oxo-tetrahydro-2H-1,3,2-oxazaphosphorin-trans-4-yl-oxyharnstoff

Conditions
ConditionsYield
With trichloroacetic acid In water at 0℃; for 20h;63%
N-hydroxyurea
127-07-1

N-hydroxyurea

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

2-(Bis-(2-chlorethyl)-amino)-r-2-oxo-tetrahydro-2H-1,3,2-oxazaphosphorin-cis-4-yl-oxyharnstoff

2-(Bis-(2-chlorethyl)-amino)-r-2-oxo-tetrahydro-2H-1,3,2-oxazaphosphorin-cis-4-yl-oxyharnstoff

Conditions
ConditionsYield
With trichloric acid In N,N-dimethyl-formamide at 0℃; for 20h;62%
2-methylpropan-2-thiol
75-66-1

2-methylpropan-2-thiol

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

(4-tert-butylsulfanyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-bis-(2-chloro-ethyl)-amine
59863-10-4

(4-tert-butylsulfanyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-bis-(2-chloro-ethyl)-amine

Conditions
ConditionsYield
In dichloromethane
mercaptoacetic acid
68-11-1

mercaptoacetic acid

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-acetic acid
71310-22-0

{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-acetic acid

Conditions
ConditionsYield
With trifluoroacetic acid
1.3-propanedithiol
109-80-8

1.3-propanedithiol

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

3-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-propane-1-thiol
65882-94-2

3-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-propane-1-thiol

Conditions
ConditionsYield
In dichloromethane
2-(2-mercaptoethoxy)ethanol
17643-17-3

2-(2-mercaptoethoxy)ethanol

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

2-(2-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-ethoxy)-ethanol
71310-27-5

2-(2-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-ethoxy)-ethanol

Conditions
ConditionsYield
With trifluoroacetic acid
3-sulfanylpropanol
19721-22-3

3-sulfanylpropanol

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

3-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-propan-1-ol
70396-83-7

3-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-propan-1-ol

Conditions
ConditionsYield
With trifluoroacetic acid
4-Mercapto-1-butanol
14970-83-3

4-Mercapto-1-butanol

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

4-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-butan-1-ol
70396-84-8

4-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-butan-1-ol

Conditions
ConditionsYield
With trifluoroacetic acid
3-mercaptopropionic acid ethyl ester
5466-06-8

3-mercaptopropionic acid ethyl ester

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

3-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-propionic acid ethyl ester
71310-26-4

3-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-propionic acid ethyl ester

Conditions
ConditionsYield
With trifluoroacetic acid
11-mercaptounadecanoic acid
71310-21-9

11-mercaptounadecanoic acid

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

11-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-undecanoic acid
71310-24-2

11-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-undecanoic acid

Conditions
ConditionsYield
With trifluoroacetic acid
6-mercapto-1-hexanol
1633-78-9

6-mercapto-1-hexanol

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

6-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-hexan-1-ol
70396-85-9

6-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-hexan-1-ol

Conditions
ConditionsYield
With trifluoroacetic acid
4-mercaptobenzoic acid
1074-36-8

4-mercaptobenzoic acid

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

4-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanylmethyl}-benzoic acid
71310-25-3

4-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanylmethyl}-benzoic acid

Conditions
ConditionsYield
With trifluoroacetic acid
4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

ethyl 2-sulfanylacetate
623-51-8

ethyl 2-sulfanylacetate

{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-acetic acid ethyl ester
71340-90-4

{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-acetic acid ethyl ester

Conditions
ConditionsYield
With trifluoroacetic acid
4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

phenylmethanethiol
100-53-8

phenylmethanethiol

(4-benzylsulfanyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-bis-(2-chloro-ethyl)-amine
59863-11-5

(4-benzylsulfanyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-bis-(2-chloro-ethyl)-amine

Conditions
ConditionsYield
In dichloromethane
4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

ethanethiol
75-08-1

ethanethiol

bis-(2-chloro-ethyl)-(4-ethylsulfanyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-amine
59863-09-1

bis-(2-chloro-ethyl)-(4-ethylsulfanyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-amine

Conditions
ConditionsYield
In dichloromethane
4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

2-hydroxyethanethiol
60-24-2

2-hydroxyethanethiol

4-(S-ethanol)-sulfido-cyclophosphamide
65882-95-3

4-(S-ethanol)-sulfido-cyclophosphamide

Conditions
ConditionsYield
In dichloromethane
4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

3-mercaptopropionic acid
107-96-0

3-mercaptopropionic acid

3-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-propionic acid
70396-87-1

3-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-propionic acid

Conditions
ConditionsYield
With trifluoroacetic acid
4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

4-mercaptobutyric acid
13095-73-3

4-mercaptobutyric acid

4-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-butyric acid
71310-23-1

4-{2-[bis-(2-chloro-ethyl)-amino]-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-ylsulfanyl}-butyric acid

Conditions
ConditionsYield
With trifluoroacetic acid
2,3,4,5,6-pentafluorobenzyloxyamine hydrochloride
57981-02-9

2,3,4,5,6-pentafluorobenzyloxyamine hydrochloride

4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

A

Z-aldophosphamide O-(2,3,4,5,6-pentafluorobenzyl)oxime

Z-aldophosphamide O-(2,3,4,5,6-pentafluorobenzyl)oxime

B

E-aldophosphamide O-(2,3,4,5,6-pentafluorobenzyl)oxime

E-aldophosphamide O-(2,3,4,5,6-pentafluorobenzyl)oxime

Conditions
ConditionsYield
In methanol; water Yield given. Yields of byproduct given. Title compound not separated from byproducts;
4-hydroxycyclophosphamide
40277-05-2

4-hydroxycyclophosphamide

4-peroxycyclophosphamide
51274-71-6, 146566-41-8

4-peroxycyclophosphamide

Conditions
ConditionsYield
With potassium hydroxide In chloroform

40277-05-2Relevant academic research and scientific papers

Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: Synthesis and deuterium labeling for applications to metabolite quantification

Ludeman,Shulman-Roskes,Wong,Han,Anderson,Strong,Colvin

, p. 393 - 398 (1995)

There is ongoing interest in the selective, quantitative analysis of the cyclophosphamide metabolites 4-hydroxycyclophosphamide (2a) and aldophosphamide (3a) because these tautomers are generally believed to play a key role in oncostatic selectivity and metabolite transport. O-(2,3,4,5,6- Pentafluorobenzyl)hydroxylamine (C6F5CH2ONH2, 1 equiv) provided for the complete conversion (by 31P NMR, 60% reaction within 15 min at 20 °C) of 2a/3a (17 mM in H2O/CH3OH) to E/Z-aldophosphamide O-(2,3,4,5,6- pentafluorobenzyl)oxime [C6F5CH2ON=CHCH2CH2OP-(O)(NH2)N(CH2CH2Cl)2; E:Z = 54:46 (±3% average deviation)]. Under these conditions, the oxime exhibited little (6%) decomposition over 3 weeks. Parallel studies showed that 4-hydroxyifosfamide/aldoifosfamide reacted completely to give the analogous aldoifosfamide oxime [C6F5- CH2ON=CHCH2CH2OP(O)(NHCH2CH2Cl)2; E:Z = 52:48 (±1% average deviation)] with 50% reaction within 15 min at 20 °C with no product decomposition over 3 weeks. In aqueous methanol and with 2 equiv C6F5CH2ONH2, clinically useful 4-hydroperoxycyclophosphamide (10 mM; τ = 10 min, 37 °C) and its isomer 4-hydroperoxyifosfamide (10 mM; τ = 25 min, 20 °C) underwent complete conversion to the corresponding aldehyde oximes. Each oxime was synthesized with deuterium in the chloroethyl moieties for use as internal standards in GC/MS applications.

Synthesis of cyclophosphamide metabolites by a peroxygenase from Marasmius rotula for toxicological studies on human cancer cells

K?nig, Rosalie,Küpper, Jan-Heiner,Kammerer, Sarah,Kiebist, Jan,Scheibner, Katrin,Schmidtke, Kai-Uwe,Steinbrecht, Susanne,Thiessen, Markus

, (2020)

Cyclophosphamide (CPA) represents a widely used anti-cancer prodrug that is converted by liver cytochrome P450 (CYP) enzymes into the primary metabolite 4-hydroxycyclophosphamide (4-OH-CPA), followed by non-enzymatic generation of the bioactive metabolites phosphoramide mustard and acrolein. The use of human drug metabolites as authentic standards to evaluate their toxicity is essential for drug development. However, the chemical synthesis of 4-OH-CPA is complex and leads to only low yields and undesired side products. In past years, fungal unspecific peroxygenases (UPOs) have raised to powerful biocatalysts. They can exert the identical selective oxyfunctionalization of organic compounds and drugs as known for CYP enzymes with hydrogen peroxide being used as sole cosubstrate. Herein, we report the efficient enzymatic hydroxylation of CPA using the unspecific peroxygenase from Marasmius rotula (MroUPO) in a simple reaction design. Depending on the conditions used the primary liver metabolite 4-OH-CPA, its tautomer aldophosphamide (APA) and the overoxidized product 4-ketocyclophosphamide (4-keto-CPA) could be obtained. Using a kinetically controlled approach 4-OH-CPA was isolated with a yield of 32% (purity > 97.6%). Two human cancer cell lines (HepG2 and MCF-7) were treated with purified 4-OH-CPA produced by MroUPO (4-OH-CPAUPO). 4-OH-CPAUPO–induced cytotoxicity as measured by a luminescent cell viability assay and its genotoxicity as measured by γH2AX foci formation was not significantly different to the commercially available standard. The high yield of 4-OH-CPAUPO and its biological activity demonstrate that UPOs can be efficiently used to produce CYP-specific drug metabolites for pharmacological assessment.

4-Peroxycyclophosphamide use thereof

-

Page/Page column 2, (2010/09/18)

4-Peroxycyclophosphamide is provided along with its method of preparation. The compound is useful for treating human cancer, particularly human primary and metastatic malignant brain tumors.

Effects of N-substitution of the activation mechanisms of 4-hydroxycyclophosphamide analogues

Kwon,Borch

, p. 1491 - 1496 (2007/10/02)

The activation mechanisms of the N-substituted 4-hydroxycyclophosphamide analogues 4-hydroxyifosfamide (2b), 4-hydroxytrofosfamide (2c), and 3-methyl-4-hydroxycyclophosphamide (2d) were compared with that of the unsubstituted parent compound 2a. The reaction kinetics of cis-2b, -2c, and -2d are qualitatively similar to those of 2a in that they undergo ring opening to the respective aldophosphamide intermediates 3, which can reclose to the cis- or trans-4-hydroxy isomers or undergo base-catalyzed β-elimination to generate the corresponding phosphoramide mustard products 4. In contrast to the general acid catalysis observed for ring opening of 2a and 2d, the N-(chloroethyl)-substituted analogues 2b and 2c undergo specific base-catalyzed ring opening. This mechanistic difference was also illustrated by the rapid action of 2a and 2d with sodium 2-mercaptoethanesulfonate (Mesna) under acidic conditions to give the 4-(alkylthio)-substituted cyclophosphamide derivatives 5a and 5d. Compounds 2b and 2c did not react with Mesna to generate 5b and 5c under these conditions. Both the fraction of aldehyde/hydrate present at equilibrium and the cytotoxicity against L1210 cells in vitro decreased in the order 2c > 2b > 2a > 2d. The plasma-catalyzed acceleration of phosphoramide mustard generation previously reported for 2a was also observed for these analogues.

The Mechanism of Activation of 4-Hydroxycyclophosphamide

Borch, Richard F.,Millard, Jo Ann

, p. 427 - 431 (2007/10/02)

4-Hydroxycyclophosphamide (2/3) of unknown stereochemistry is the initial metabolite formed after administration of cyclophosphamide (1).Ultimate conversion to the cytotoxic metabolite phosphoramide mustard (6) is initiated by ring opennig of 4-hydroxycyclophosphamide to produce aldophosphamide (4).The ring-opennig reaction and subsequent equilibration of 2-4 are subject to general-acid catalysis, and the equilibrium composition is independent of buffer structure and pH.In contrast, formation of 6 from 4 proceeds by general-base-catalyzed β-elimination. trans-4-Hydroxycyclophosphamide undergoes ring opening ca. 4 times faster than the cis isomer, and cyclization of 4 favors the trans isomer by a factor of ca. 3 over the cis isomer.The rapid equilibration of 2-5 and the absence of elimination to give 6 at pH ca. 5 provides a convenient method to prepare a stable equilibrium mixture of activated cyclophosphamide metabolites suitable for in vitro use.

Activation Mechanisms of Mafosfamide and the Role of Thiols in Cyclophosphamide Metabolism

Kwon, Chul-Hoon,Borch, Richard F.,Engel, Jurgen,Niemeyer, Ulf

, p. 395 - 399 (2007/10/02)

cis-Mafosfamide (cis-5) (ASTA Z7557), a stable analogue of cis-4-hydroxycyclophosphamide (cis-2), undergoes rapid decomposition in aqueous phosphate buffer or plasma at pH 7.4 and 37 deg C.The reaction kinetics of cis-5 are complex, and trans-mafosfamide (trans-5) and cis-2 are produced and subsequently disappear over the course of the reaction.The rates of decomposition of cis-5 as well as cis-2 were much faster in plasma than in buffer.The cis-trans isomerization of cis-5 occured by a specific-base-catalyzed process via iminocyclophosphamide (8) as a transient intermediate.In contrast, formation of cis- and trans-mafosfamide (5) from cis-2 and MESNA (sodium 2-mercaptoethanesulfonate) proceeded by an acid-catalyzed process via the hemithioacetal intermediate (6).The significance of these findings with respect to cyclophosphamide metabolism is discussed.

31P Nuclear Magnetic Resonanse Spectroscopic Observation of the Intracellular Transformations of Oncostatic Cyclophosphamide Metabolites

Boyd, Victoria L.,Robbins, Joan D.,Egan, William,Ludeman, Susan M.

, p. 1206 - 1210 (2007/10/02)

(31)P NMR spectroscopy was used to directly monitor, for the first time, the intracellular chemistry of the ultimate active metabolite of cyclophosphamide, namely, phosphoramide mustard.These NMR studies utilized a human histiocytic lymphoma cell line (U937), embedded in agarose gel threads, and perfused with medium containing synthetically derived metabolites (4-hydroxycyclophosphamide (2), aldophosphamide (3), and phosphoramide mustard (4)).Metabolites 2 or 3 or both readily crossed the cell membrane; in contrast, the membrane was relatively impermeable to 4.Intracellular concentrations of 4 could, therefore, be attributed primarily to the intracellular fragmentation of 3.Signals suggestive of either carboxyphosphamide or 4-ketophosphamide were not detected.Spectral data were used to calculate a rate constant of (5.4 +/- 0.3) * 10-3 min-1 for the intracellular disappearance of 4 at 23 deg C.The intracellular pH was determined to be 7.1 from the chemical shift of the internal inorganic phosphate signal.

In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution

Borch,Hoye,Swanson

, p. 490 - 494 (2007/10/02)

cis-4-Hydroxycyclophosphamide (2) and aldophosphamide (4) were generated in aqueous phosphate or cacodylate buffer by dimethyl sulfide reduction of cis-4-hydroperoxycyclophosphamide and by sodium periodate cleavage of 3,4-dihydroxybutyl N,N-bis(2-chloroethyl)phosphorodiamate, respectively; the reactions of 2 and 4 were examined by 1H and 31P NMR. Within 30-60 min (pH or pD 7.0, 25 °C) the same pseudoequilibrium mixture was established in both reactions, with cis- and trans-4-hydroxycyclophosphamide (2 and 3), aldophosphamide (4), and its hydrate (5) present in the approximate ratio of 4:2:0.3:1. Structures of the intermediates were assigned unambiguously based upon analysis of the chemical shifts and coupling constants in the proton spectra determined in D2O buffers, and the 31P assignments followed by correlation of component ratios at equilibrium. Free energy differences of 0.4, 0.4, and 0.7 kcal/mol at 25 °C were estimated between 2, 3, 5, and 4, respectively, with 2 being the most stable. The aldehyde 4 reacted most rapidly with water to give hydrate 5; cyclization of 4 to 3 occurred faster than to 2. Compound 5 is formed much faster than 3 from the diol cleavage, but 5 and 3 are produced at comparable rates from 2, suggesting that conversion of 2 to 3 can proceed by a mechanism other than ring opening. The rate of equilibration appears to be independent of buffer structure, indicating that bifunctional catalysis is not important in the ring-opening reaction. β-Elimination from 4 is rate limiting for the production of acrolein, and the rate for phosphate is 2- to 3-fold faster than for cacodylate under identical conditions. These results provide the first definitive evidence for the stability of the elusive aldehyde 4 in aqueous solution and for the existence of a preequilibrium among 2-5 prior to rate-limiting expulsion of phosphoramide mustard from 4.

NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of cis- and trans-4-Hydroxycyclophosphamide with Aldophosphamide and the Concomitant Partitioning of Aldophosphamide between Irreversible Fragmentation ...

Zon, Gerald,Ludeman, Susan Marie,Brandt, Joan A.,Boyd, Victoria L.,Oezkan, Gunay,et al.

, p. 466 - 485 (2007/10/02)

Multinuclear (31P, 13C, 2H, and 1H) Fourier-transform NMR spectroscopy, with and without isotopically enriched materials, was used to identify and quantify, as a function of time, the following intermediary (short-lived) metabolites of the anticancer prodrug cyclophosphamide (1, Scheme I): cis-4-hydroxycyclophosphamide (cis-2), its trans isomer (trans-2), aldophosphamide (3), and its aldehyde-hydrate (5).Under a standard set of reaction conditions (1 M 2,6-dimethylpyridine buffer, pH 7.4, 37 deg C), the stereospecific deoxygenation of synthetic cis-4-hydroperoxycyclophosphamide (cis-12, 20 mM) with 4 equiv of sodium thiosulfate (Na2S2O3) afforded, after ca.20 min, a "pseudoequilibrium" distribution of cis-2, 3, 5, and trans-2, i.e., the relative proportions of these reactants (57:4:9:30, respectively) remained constant during their continual disappearance.NMR absorption signals indicative of "iminophosphamide" (8) and enol 6 were not detected ( "3" trans-2, as well as the rate constant (k3) for the irreversible fragmentation of 3.The values of k3 at pH 6.3, 7.4, and 7.8 were equal to 0.030 +/- 0.004, 0.090 +/- 0.008, and 0.169 +/- 0.006 min-1, respectively.Replacement of the HC(O)CH2 moiety in 3 with HC(O)CD2 led to a primary kinetic isotope effect (kH/kD = 5.6 +/- 0.4) for k3.The apparent half-lives (τ*1/2) for cis-2, "3", and trans-2 under the standard reaction conditions, at "pseudoequilibrium" (constant ratio of cis-2/"3"/trans-2), were each equal to ca.38 min, which is considerably shorter than the widely cited colorimetrically derived half-lives reported by earlier investigators.The values of τ*1/2 for cis-2, "3", and trans-2 were affected by pH in the same manner as that found for k3 but were relatively insensitive to the presence of either K(+), Na(+), Ca(2+), or Mg(2+).The presence of certain primary amines led to marked decreases in τ*1/2 and, in some cases, the formation of acyclic adducts of aldehyde 3.The relatively stable adduct formed from 3 and tris(hydroxymethyl)aminomethane (Tris) at pH 7.4 and 37 deg C gave rise to a 31P NMR signal that other investigators have mistakenly ascribed to 2. 31P NMR spectroscopy was also used to examine, in considerable detail, the manifold effects of N-acetyl-L-cysteine upon the chemistry of 2, "3", and 4, which featured the formation of a mixture of diastereomeric, acyclic ...

Base-catalyzed hydrolysis of 4-hydroperoxycyclophosphamide: Evidence for iminocyclophosphamide as an intermediate

Borch,Getman

, p. 485 - 490 (2007/10/02)

cis-4-Hydroperoxycyclophosphamide (5) undergoes facile reaction with acqueous phosphate or Tris buffers at pH 7-8 and 30 °C. The kinetics of 5 are complex,and the trans-4-hydroperoxy isomer 6 is produced and subsequently disappears over the course of the reaction. Addition of hydrogen peroxide to the reaction mixture retards the disappearance rate of 5 and increases the amount of 6 generated. Rate constants for the reversible disappearance of 5 and appearance of 6 and 4-hydrocyclophosphamide (2) have been determined by nonlinear least-squares methods. The reaction is catalyzed by hydroxide ion, Tris free base, and HPO42-, with catalytic constants of 0.032 min-1 (pH 8.0), 0.052, and 0.115 M-1, respectively. The major product in the presence of Tris is the oxazolidine arising from the addition of Tris to aldophosphamide, not 2 as assumed previously. These results are consistent with a mechanism involving general-base-catalyzed elimination to produce iminocyclophosphamide as a transient intermediate; the imine can react with the hydrogen peroxide evolved in the reaction to give 5 and 6, with water to give 2, or, in general, by addition of a nucleophile to C-4. The significance of these findings with respect to other 4-substituted cyclophosphamides is discussed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 40277-05-2